Main Story
-
RIMAN Highlights Product and Ingredient Innovation at RIMAN North America Convention 2026
SEOUL, South Korea, Aug. 14, 2026 /PRNewswire/ — RIMAN, a direct selling company specializing in K-beauty skincare and wellness, successfully concluded its North America Convention 2026 in Las Vegas, Nevada, from August 7–9, 2026. The three-day event brought together thousands of distributors and sales leaders from across North America to celebrate business achievements, discover product…
Products
-
AccuSure AS9 Fully Automatic Digital Blood Pressure Monitor With Large Display
Original price was: ₹1,733.00.₹998.00Current price is: ₹998.00. -
AGEasy Max Group Fully Automatic One Touch Digital Blood Pressure Monitoring Device
Original price was: ₹1,405.00.₹949.00Current price is: ₹949.00. -
Automatic Digital Blood Pressure Monitor for Upper Arm, Large LCD Display
Original price was: ₹2,399.00.₹448.00Current price is: ₹448.00. -
Beurer German Engineering P0 13 Kid’s Pulse Oximeter I Fingertip Home Pulse Oximeter
Original price was: ₹2,745.00.₹1,538.00Current price is: ₹1,538.00. -
BPL Medical Technologies Bluetooth Enabled Arm Type Blood Pressure Monitor
Original price was: ₹6,563.00.₹5,199.00Current price is: ₹5,199.00.
Automobile
Tech
Entertainment
Health
-
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy Source: BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
-
Avicanna Reports Q2 2026 Financial Results
Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured Source: Avicanna Reports Q2 2026 Financial Results
-
More Cancer Patients Are Opting to Preserve Their Tumors
New Tumor-Preservation Service Opens in Arizona, Giving Patients the Chance to Preserve Tumor Tissue for Potential Personalized Dendritic Cell Therapy Source: More Cancer Patients Are Opting to Preserve Their Tumors
-
Axtria to Build Industry’s Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026
NEW DELHI, Aug. 13, 2026 /PRNewswire/ — Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced plans to expand its Forward Deployed Engineering (FDE) organization to 1,000 engineers by December 2026, creating the industry’s largest pharma-specific AI engineering team. The expansion represents one of Axtria’s largest investments in AI…
-
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2026, and provided a business…
-
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI, Aug. 13, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the Investigational New Drug (IND) application for AK0406 injection, the company’s first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
